Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + cemiplimab + platinum-doublet chemotherapy versus cemiplimab + chemotherapy for first-line advanced NSCLC
MOH_2023-11-28_013074Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fianlimab and cemiplimab in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Regeneron Pharmaceuticals. Started Nov 2023; status: recruiting.
02
Drugs
fianlimabcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2023-11-28_013074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-28_013074.